Alira Health

Alira Health

Management Consulting

Integrated Launch Planning

A fully coordinated, holistic approach

Benefit from Alira Health’s full spectrum of strategy and advisory services to ensure successful outcomes for all of your business stakeholders: patients, providers, payers, and suppliers.

Elevating industry best practices and innovation

Integrated launch planning (ILP) is recognized as an essential best practice. Alira Health provides full spectrum support to coordinate key launch deliverables in a transparent, collaborative way. This allows functions and markets across your organization to focus on the path towards launch in a more holistic, integrated way—a critical key to success.

The purpose of the ILP is not to replace functional launch plans—it’s to provide high-level leadership that delivers an integrated view of the whole picture. As your partner, Alira Health will highlight potential needs for analysis and inquiry if delays are anticipated.

Why choose Alira Health?

Whether your in-house teams are launching products across a multitude of therapeutic areas or you’re a BioTech company relying on third-party service providers, we will help you translating your launch strategy into a robust, executable plan.

Our experienced global team will actively engage with your organization to:

  • Structure your launch preparations and define appropriate launch governance
  • Meet with critical workstream teams to identify key deliverables and essential interdependencies
  • Deliver an integrated launch plan tool that is easy to update and provides customized status reports

Connect with a Winning Team

See why Alira Health was named one of the world’s best management consulting firms by Forbes.

Related news

Case Studies March 26, 2024
Pharma Company Overcomes Launch Challenges with Patient-Centric Strategy
Our patient engagement team helped this pharma client identify the drivers behind the challenges they faced with their product launch.
Patient Centricity Patient Engagement Pharma
Case Studies March 12, 2024
Pharma Company Adopts a Patient-Centric Value Proposition for Regulatory and Payer Dossier
A pharma company had a wealth of patient data on a product in development and they wanted to create a long-term strategy that would create a continuity of patient engagement across(...)
Patient Centricity Patient Engagement Pharma
News February 7, 2024
Alira Health Advises Aesculapius Farmaceutici Srl in Its Acquisition by Ceres Pharma NV
We are pleased to have represented as transaction advisor Aesculapius, a leading Italian pharmaceutical company active in the development and distribution of prescription drugs, OTC(...)
Pharma Transaction Advisory
News January 26, 2024
Alira Health’s CDD Supports Alcami Acquisition of Pacific Pharmaceutical Services
We are pleased to have been an advisor on Alcami’s acquisition of Pacific Pharmaceutical Services (PPS). Alira Health advised Alcami, a leading Contract Development Manufacturing(...)
CDD CDMO Pharma
Events January 22, 2024
Pharmapack Europe
Connect with our Drug Delivery Systems and CDMO experts Aude Ouensanga, Giulia Valsecchi, and Michal Raciborski on site at Pharmapack Europe.
CDMO Drug Delivery Pharma
Case Studies January 18, 2024
Pharma Company Succeeds in Adding Medicine to World Health Organization Essential Medicines List
A pharma company with a blood disorder treatment needed support to submit a value dossier to the WHO to add a medicine to the Essential Medicines List.
Market Access Pharma
Case Studies January 8, 2024
Pharma Company Extends to New Markets through Strategic Licensing Agreements
A Swedish pharma company saw a market opportunity to expand access to its proprietary product outside of the Nordics and sought support developing strategic licensing deals.
Market Access Pharma
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.